+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
R

Actively Recruiting

Researchers are comparing durvalumab immunotherapy to the usual post-surgery observation approach for people with early-stage non-small cell lung cancer who have no remaining cancer cells after standard treatment. This phase III trial focuses on patients with stage II to IIIB disease who achieved a complete response following neoadjuvant chemo-immunotherapy. The study aims to find out whether durvalumab can help patients live longer and prevent cancer from coming back compared to just monitoring after surgery. Participants are randomly assigned to one of two groups. One group receives durvalumab intravenously once every 28 days for up to 12 cycles, provided there is no disease progression or unacceptable side effects. The other group undergoes active surveillance without additional treatment for 12 months. During the trial, all participants have regular CT scans and blood samples taken. After treatment or surveillance, patients are followed annually for up to 10 years. Throughout the study, participants complete questionnaires assessing quality of life and symptoms. Researchers monitor disease-free survival, overall survival, and adverse events up to 10 years after randomization. The trial also collects specimens and images for future research. Participants have regular visits for scans, blood tests, and assessments to evaluate the safety and effects of durvalumab compared to observation.

Age: 18Years +All GendersPhase 3
284 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
C

Actively Recruiting

Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.

Age: 18Years +All GendersPhase 3
802 locations
E

Actively Recruiting

Researchers are evaluating the combination of osimertinib and bevacizumab versus osimertinib alone as first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has spread beyond the lungs stage IIIB-IV and involves mutations in the EGFR gene. This phase III trial aims to determine if adding bevacizumab, which stops blood vessel growth to tumors, can better control cancer progression and improve survival compared to osimertinib alone. The study also examines overall survival, response rates, central nervous system progression, and treatment toxicity. Participants are randomly assigned to one of two groups one receives oral osimertinib daily, and the other receives oral osimertinib daily plus bevacizumab intravenously every 21 days. Treatment cycles repeat every 21 days unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo various imaging tests including echocardiography, multigated acquisition scans, computed tomography, and possibly magnetic resonance imaging. Blood and urine samples are also collected to study treatment effects and resistance mechanisms. After finishing treatment, participants are monitored every three months for up to 10 years to track disease progression and survival. The main outcome measured is progression-free survival, defined as the time from starting treatment until cancer worsens or death. Secondary outcomes include overall survival, response rates, central nervous system involvement, and treatment safety. Regular assessments and sample collections help researchers understand how the treatments work and their long-term effects.

Age: 18Years +All GendersPhase 3
604 locations
C

Actively Recruiting

Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.

Age: 18Years +All GendersPhase 3
846 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
T

Actively Recruiting

Researchers are studying the use of FDA-approved targeted therapies for patients with advanced cancer whose tumors have specific genomic changes that may respond to these drugs. This non-randomized Phase 2 trial aims to understand the safety and effects of these targeted anticancer treatments in real-world clinical practice. The study catalogs molecular profiling tests used by doctors and helps develop ideas for further clinical trials. Participants receive one of several targeted drug treatments based on their tumors genetic profile. These include drugs such as sunitinib, trastuzumab with pertuzumab, vemurafenib with cobimetinib, olaparib, nivolumab with ipilimumab, abemaciclib, talazoparib, atezolizumab with talazoparib, tucatinib with trastuzumab, futibatinib, dabrafenib with trametinib, or fam-trastuzumab deruxtecan-nxki. Dosage, frequency, and duration follow approved labeling. Each drug is matched to specific genomic variants identified in the tumor. Participants must be at least 12 years old and have advanced cancer that is no longer benefiting from standard treatment or for which no approved therapy is available. They undergo genomic testing to identify actionable tumor variants and receive treatment accordingly. Researchers assess tumor response at 16 weeks and monitor overall survival for up to 3 years. Safety and treatment effects are observed throughout the study, which lasts until 2028, with results shared publicly as they become available.

Age: 12Years +All GendersPhase 2
181 locations
E

Actively Recruiting

Researchers are evaluating the addition of tivozanib to standard pembrolizumab immunotherapy for patients with high-risk renal cell carcinoma RCC after surgery. This phase III trial aims to compare disease-free survival and overall survival between patients receiving pembrolizumab alone and those receiving pembrolizumab combined with tivozanib. The study also assesses side effects, patient quality of life, and will bank specimens for future research. Participants are randomly assigned to one of two groups. One group receives pembrolizumab intravenously on specific days every 12 weeks for up to 4 cycles. The other group receives pembrolizumab on the same schedule plus oral tivozanib daily on specified days within each cycle for up to 6 months. Both groups undergo regular blood sample collection and imaging scans like MRI or CT, and may have tissue biopsies during the study. After treatment, participants are followed with visits every 4 months for 2 years, then every 6 months for 3 years, and annually for 5 more years. Researchers monitor disease recurrence, survival, side effects, and treatment tolerance. Patient-reported fatigue and overall quality of life are also measured throughout the study to understand the impact of the treatments over time.

Age: 18Years +All GendersPhase 3
429 locations

1-10 of 12

1